Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now full pipeline small index

Growth Hormone Deficiency (GHD): full-pipeline trial registry

1 of 2 indexed Growth Hormone Deficiency (GHD) trials are currently recruiting.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count

Growth Hormone Deficiency (GHD): 2 US clinical trials tracked, 1 recruiting.

Growth Hormone Deficiency (GHD) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is OPKO Health, running 1 of these trials.

Enrollment posture brief

Registry condition growth-hormone-deficiency-ghd

OPEN 1 | RECR 50% | LATE 1 | EARLY 1 | RANK #7188 | SPON 1

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Growth Hormone Deficienc (th…50%
Open-enrollment share among volume-matched conditions near Growth Hormone Deficiency (GHD)

Growth Hormone Deficiency (GHD) lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Growth Hormone Deficiency (GHD) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Growth Hormone Deficiency (GHD) is recruiting above its size-band peers.

    1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21Phase 31

Phase Distribution

PhaseTrial count
Phase 2 1
Phase 3 1

Top Sponsors

OPKO Health 1 trials
Lumos Pharma 1 trials

Named interventions

Most-linked intervention names on Growth Hormone Deficiency (GHD) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

MOD-4023 Drug
1 trials
Matched Placebo (Capsules) Other
1 trials
LUM-201 Drug
1 trials

US sites by state

Facility locations filed on Growth Hormone Deficiency (GHD) trials. A trial with sites in several states counts in each.

Florida 2 trials
Washington 1 trials
Texas 1 trials
South Carolina 1 trials
New York 1 trials
Nevada 1 trials
New Jersey 1 trials
Missouri 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Growth Hormone Deficiency (GHD) page

2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Growth Hormone Deficiency (GHD) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • OPKO Health sponsors the most Growth Hormone Deficiency (GHD) trials on record, review their full trial history before evaluating a specific study. See OPKO Health's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Growth Hormone Deficiency (GHD) condition card totals 2 registered trials; most-linked intervention MOD-4023; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.